Berobenatide: Pfizer Weight Loss Drug, Monthly Shot Results

The short answer

Berobenatide (PF-08653944, formerly MET-097i) is Pfizer's experimental GLP-1 weight loss shot, built to be taken once a month after a weekly start. In a mid-stage trial it led to up to 12.3% more weight loss than placebo at 28 weeks. It is not FDA approved and has no price. On November 11, 2026, Blackstone agreed to fund up to $1.5 billion of its Phase 3 costs. Fewer shots do not protect muscle, so Sharpy gives you one protein target, one 20-minute workout and one Shape Score a day.

What is berobenatide? It is the Pfizer weight loss drug that made news this week. Berobenatide (PF-08653944, once called MET-097i) is an experimental GLP-1 shot. The plan is weekly shots for about three months, then one shot a month. It is not FDA approved, and you cannot buy it. On November 11, 2026, Pfizer said Blackstone will pay up to $1.5 billion toward its Phase 3 trials.

Here is what is known so far, in plain English.

Berobenatide at a glance

Question Answer Source
Who makes it? Pfizer (from its Metsera purchase, November 2025) Pfizer
Other names PF-08653944, PF'3944, MET-097i, MET097 Pfizer, ClinicalTrials.gov
Drug type GLP-1 receptor agonist peptide Pfizer
How it is taken Shot under the skin. Weekly at first, then monthly Pfizer VESPER-3 release
Half-life About 15.5 days Healio, ADA 2026 report
Approved? No. Phase 3 trials are running Pfizer
Price Not announced Not stated anywhere

What is the name of Pfizer's weight loss drug?

The name is berobenatide. People also search for it as "the Pfizer weight loss injection" or by its old Metsera code, MET-097i.

Pfizer did not invent it. A biotech called Metsera did. Pfizer won a bidding war against Novo Nordisk and bought Metsera in November 2025. News reports put the winning offer at about $10 billion. Before that, Pfizer had tried to make its own weight loss pills and stopped those programs.

So the honest answer to "does Pfizer have a weight loss drug?" is: not on the market yet. Berobenatide is its best shot at one.

How does berobenatide work?

It copies GLP-1, the same gut hormone that Ozempic and Wegovy copy. That lowers appetite and slows the stomach. Our guide on how GLP-1 works covers the basics.

Two things make berobenatide different:

  • It lasts a long time. Doctors at the American Diabetes Association meeting in June 2026 reported a half-life of about 15.5 days. Semaglutide's is about one week. That is why monthly dosing is possible.
  • Pfizer calls it "fully biased." In simple words, it switches on one signal inside the cell much more than another. The idea is a longer effect and maybe fewer stomach problems. That second part is still a theory.

Healio describes it as a peptide made of 41 amino acids. It is a GLP-1 only drug. It does not act on GIP the way Zepbound does.

Berobenatide trial results: how much weight did people lose?

The key study so far is VESPER-3, a Phase 2b trial in adults with obesity or overweight and no diabetes. People took weekly shots for 12 weeks. Then they switched to a monthly shot of 3.2 mg or 4.8 mg. Each group had about 54 people.

Pfizer shared the 28-week results on February 3, 2026:

Group Monthly dose after week 12 Extra weight loss vs placebo at 28 weeks
Arm 1 3.2 mg 10.0%
Arm 3 4.8 mg 12.3%

When Pfizer counted everyone, including people who stopped the drug, the numbers were 8.4% and 10.5%. Pfizer said there was no plateau at week 28. The study runs to week 64, and those final numbers are not out yet.

Two more pieces came out at the June 2026 diabetes meeting:

  • Longer use. In an extension of an earlier study, people on the 4.8 mg monthly dose were down about 15% from their starting weight at 60 weeks, according to Healio.
  • Type 2 diabetes. In VESPER-2, weekly berobenatide led to up to 10.2% weight loss and an A1C drop of up to 2.2 points at 28 weeks.

Pfizer plans to test a higher monthly dose, 9.6 mg, in Phase 3.

Keep this in view: 28 weeks is short. Wegovy and Zepbound trials ran 68 to 72 weeks. You cannot fairly line up these numbers side by side yet.

What are berobenatide side effects?

The pattern looks like other GLP-1 drugs. Stomach problems lead the list.

  • Reuters reported average rates across the VESPER-3 groups of about 38% for nausea and about 23% for vomiting. For comparison, the Wegovy label lists 44% and 24%.
  • 83% of people on the drug had no stomach side effects or only mild ones.
  • Most problems came during the weekly step-up phase.
  • After the switch to monthly, nausea and vomiting rose a little for a short time, then settled.
  • In the two groups Pfizer is taking forward, 10 people stopped because of side effects. No one on placebo did.

Pfizer says its Phase 3 trials will raise the dose more slowly to make the monthly switch easier. No body composition data, such as how much of the weight lost was muscle, has been published.

If nausea is your main worry on any GLP-1, see managing nausea.

The Blackstone deal: what the $1.5 billion means for patients

On November 11, 2026, Pfizer and Blackstone Life Sciences announced a funding agreement. The facts from Pfizer's release:

  • Blackstone funds will cover up to $1.5 billion of berobenatide development costs through 2028.
  • Blackstone gets paid later only if the monthly shot wins US approval for weight management and hits certain sales goals. The amounts were not shared.
  • Blackstone gets no ownership of the drug. Pfizer keeps full control.

For patients, this changes nothing today. It does show that Pfizer is running a very large program and has the money lined up to finish it.

Berobenatide Phase 3 trials

Pfizer says it has 10 ongoing and planned Phase 3 trials. ClinicalTrials.gov lists these, among others:

Trial Who and how Size Main results window
VESPER-4 Weekly shot, obesity without diabetes 3,578 enrolled 64 weeks. Main phase ends about September 2027
VESPER-5 Weekly shot, obesity with type 2 diabetes 1,078 enrolled 64 weeks. About October 2027
VESPER-6 Monthly shot, obesity or overweight 954 planned 72 weeks. About May 2028
VESPER-SWITCH People already on weekly semaglutide or tirzepatide move to monthly berobenatide 660 planned 32 weeks. About February 2028
VESPER-OSA trials Monthly shot, sleep apnea 258 planned each 52 weeks. 2028
VESPER-OA trials Knee osteoarthritis 756 and 656 planned 52 weeks. 2028
VESPER-SUI Women with stress urinary incontinence 900 planned 52 weeks. 2028

VESPER-SWITCH is the one many current users will care about. It asks a simple question: if you are doing well on Wegovy or Zepbound, can one shot a month hold your weight?

How does berobenatide compare with other monthly shots?

It is not alone. Amgen's MariTide is also in Phase 3 with monthly dosing, and its Phase 2 trial ran a full 52 weeks. Viking is testing monthly maintenance doses of VK2735. China's bofanglutide is another once-monthly GLP-1. None of them is FDA approved. For what you can get today, see the GLP-1 drugs list.

What to do while you wait

A monthly shot may be two years away or more. The things that shape your results on any GLP-1 are the same today:

This is what Sharpy is built for. It gives you one protein target, one 20-minute workout and one Shape Score a day, whether your shot is weekly now or monthly later.

Do not buy "berobenatide" or "MET-097i" from peptide sites. It is an unapproved drug, and nobody checks what is in those vials. If a clinical trial interests you, ask your doctor and look up the VESPER studies on ClinicalTrials.gov.

Twelve shots a year instead of 52 sounds great. It also means fewer weekly reminders that you are on treatment. Daily habits will matter even more, and Sharpy keeps them in front of you.

Sources

Questions people ask

What is berobenatide?

Berobenatide is an experimental GLP-1 receptor agonist made by Pfizer. It is a peptide given as a shot under the skin. Pfizer is testing it as a weekly shot and as a once-monthly shot for chronic weight management. It is also known as PF-08653944, PF'3944 and MET-097i.

What is the name of Pfizer's weight loss drug?

Pfizer's lead weight loss drug is berobenatide. Pfizer got it when it bought the biotech company Metsera in November 2025. Pfizer has no FDA-approved weight loss drug today. Its earlier pills were dropped during testing.

Is berobenatide FDA approved?

No. Berobenatide is investigational and is not approved in any country. Phase 3 trials are running now. The first big trial is due to finish its main phase in September 2027, according to ClinicalTrials.gov. Zacks reports that Pfizer is aiming for a first approval in 2028. Pfizer has not announced a filing date.

How much weight can you lose on berobenatide?

In the VESPER-3 Phase 2b trial, the best group lost 12.3% more body weight than the placebo group at 28 weeks. Pfizer said weight was still dropping at that point. Longer Phase 3 trials of 64 to 72 weeks will show the full effect.

What are berobenatide side effects?

The main ones so far are stomach related. Reuters reported average rates across the VESPER-3 groups of about 38% for nausea and about 23% for vomiting. Most cases were mild or moderate, and most happened while the dose was going up.

Is berobenatide a monthly shot from the start?

No. In trials, people start with weekly shots at low doses for about 12 weeks. Then they switch to one shot a month. Pfizer is also testing a weekly-only version in two large Phase 3 trials.

How much will berobenatide cost?

Nobody knows yet. Pfizer has not shared a price, and there will not be one until the drug is approved. Be careful with any website that sells "berobenatide" or "MET-097i" today. It is not a legal, approved medicine.

Read next